GLTO - Galecto Inc
IEX Last Trade
12.01
-0.115 -0.958%
Share volume: 130,327
Last Updated: Fri 30 Aug 2024 09:09:44 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$12.12
-0.12
-0.95%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-10.20%
1 Month
-13.55%
3 Months
-20.49%
6 Months
-30.85%
1 Year
-16.67%
2 Year
-78.73%
Key data
Stock price
$12.01
DAY RANGE
N/A - N/A
52 WEEK RANGE
$11.50 - $23.50
52 WEEK CHANGE
-$0.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO:
Region: US
Website: galecto.com
Employees: 61
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: galecto.com
Employees: 61
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
galecto biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. the company’s products target galectins, a group of proteins that play important roles in many disorders. galecto biotech’s high potency galectin modulators may open new treatment possibilities for many patients. the company, which is located in lund, sweden, is led by top-level scientists and biotech executives.
Recent news